Press release
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
– Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures - – Patient survey data demonstrate treatment
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures -\n\n\n– Patient survey data demonstrate treatment burden associated with injectable on-demand treatments for HAE -\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop (C1 Workshop) in Budapest, Hungary.\n\n\nThe following presentations occurred at the 2023 C1 Workshop:\n\n\n\nRationale for the Short-term Prophylaxis Regimen with Sebetralstat in KONFIDENT-S: Michael D. Smith, KalVista Pharmaceuticals Inc., Cambridge, MA, USA (oral presentation)\n\n\n\nHAE Patients Decision to Carry On-demand Treatment When Away from Home: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON Canada (oral presentation)\n\n\n\nRoute of Administration Preferences of People with Hereditary Angioedema for On-demand Treatment: A US-based Qualitative Study: Laurence Bouillet, Internal Medicine, Grenoble Alpes University, National Reference Center for Angioedema, Grenoble, France (poster presentation)\n\n\n\nIn the first oral presentation, KalVista presented data providing the rationale for the sebetralstat regimen for short-term prophylaxis (STP) for medical and dental procedures in people living with hereditary angioedema (HAE) in the phase 3 KONFIDENT-S trial, which is an ongoing, up to 2-year, open-label extension of the phase 3 KONFIDENT trial.\n\n\nThe second oral presentation was based on real-world survey data collected from people with HAE and showed that only one-third of patients always carry on-demand attack treatment with them when away from home. Of note, those that did not carry treatment would routinely travel for several hours without it for a variety of reasons, including a preference to treat with injectables at home.\n\n\nThe poster presentation, based on qualitative interviews with adolescents and adults with HAE, demonstrated that both groups had a strong preference for oral medication for on-demand trea...